Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07276789

Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

Led by Integro Theranostics · Updated on 2026-04-20

35

Participants Needed

2

Research Sites

38 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) infusion in patients undergoing VATS (Video-Assisted Thoracoscopic Surgery) or RATS (Robotic-Assisted Thoracoscopic Surgery) resection of Stage I-II non-small cell lung cancer (NSCLC).

CONDITIONS

Official Title

Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Have a primary diagnosis or strong suspicion of lung cancer based on CT, biopsy, or imaging
  • Scheduled for lung tumor removal surgery using thoracoscopy
  • For those who can become pregnant, negative serum pregnancy test before dosing and use of medically accepted contraception or abstinence
  • Able to understand and follow study requirements
Not Eligible

You will not qualify if you...

  • Medical conditions or contraindications that make surgery unsafe
  • History of drug-related allergic or anaphylactic reactions, including to indocyanine green or other contrast agents
  • Impaired kidney function
  • Clinically significant ECG abnormalities or heart conduction issues
  • Prior radiation therapy to the chest
  • Elevated total bilirubin levels above 1.5 times the upper limit
  • Elevated liver enzymes (AST/SGOT or ALT/SGPT) above 2.5 times the upper limit
  • Pregnant or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

2

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

Loading map...

Research Team

J

Jim Joffrion

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer | DecenTrialz